Showing 4911-4920 of 20470 results for "".
- AAD 2026: Revance to Showcase Expanding Aesthetics Portfoliohttps://reachmd.com/news/aad-2026-revance-to-showcase-expanding-aesthetics-portfolio/2486383/Revance Therapeutics Inc. announced it will showcase its expanding portfolio of aesthetics, regenerative medicine, and consumer skincare products at the 2026 American Academy of Dermatology (AAD) Annual Meeting, scheduled for March 26–31 in Denver, Colorado. The company plans a series of in-booth
- FDA Clears Full-Wavelength Capability for Lasermach Laser Systemhttps://reachmd.com/news/fda-clears-full-wavelength-capability-for-lasermach-laser-system/2486382/Wingderm announced that its Lasermach laser system has received expanded clearance from the US Food and Drug Administration (FDA), enabling use across all 3 wavelengths—755 nm, 808 nm, and 1064 nm. The update includes clearance for a mixed-wavelength handpiece combining all 3 wavelengths, as well
- Perceived Social Support, Resilience, Mindfulness, and Learning Engagementhttps://reachmd.com/news/perceived-social-support-resilience-mindfulness-learning-engagement/2486377/Among Chinese vocational students, investigators report that higher perceived social support was associated with higher learning engagement, with emotional resilience and mindfulness modeled as m
- Maternal Antibodies and Neonatal Protection from E. coli Sepsishttps://reachmd.com/news/maternal-antibodies-neonatal-protection-e-coli-sepsis/2486378/In a recent study published in Nature, lower maternally transferred anti–E. coli antibodies at birth were observed among infants who later developed severe infection.
- Prospective Data Show Comparable Performance Between AI and Dermatologistshttps://reachmd.com/news/prospective-data-show-comparable-performance-between-ai-and-dermatologists/2486375/A new systematic review and meta-analysis of prospective studies suggests artificial intelligence (AI) systems can achieve diagnostic performance comparable to dermatologists in melanoma detection using dermoscopy. Investigato
- Facility Volume and Endometrial Cancer: Treatment Patterns and Outcomeshttps://reachmd.com/news/facility-volume-and-endometrial-cancer-treatment-patterns-and-outcomes/2486368/A multicenter retrospective cohort from Emilia-Romagna, Italy, reported in facility volume and endometrial cancer, compared medium-volume centers (11–29 endometrial cancer cases/year) with high-
- Rapid Fecal Calprotectin: CerTest card vs Actim and Calprest ELISAhttps://reachmd.com/news/rapid-fecal-calprotectin-certest-card-vs-actim-and-calprest-elisa/2486361/In patients clinically suspected of inflammatory bowel disease, a head-to-head evaluation compared rapid fecal calprotectin formats—including the CerTest Calprotectin one-step card, an Actim later
- BioNTech’s ELCC 2026 Lung Cancer Datahttps://reachmd.com/news/biontechs-elcc-2026-lung-cancer-data-portfolio-updates-and-clinical-signals/2486359/BioNTech’s company press release detailing its ELCC 2026 lung cancer presentations ou
- FDA Approves Restylane Contour for Temple Hollowing Correctionhttps://reachmd.com/news/fda-approves-restylane-contour-for-temple-hollowing-correction/2486354/Galderma announced that the U.S. Food and Drug Administration (FDA) has approved Restylane® Contour™ for the correction of temple hollowing in patients aged 21 years and older, expanding its indications beyond cheek augmentation and midface contour deficiencies. The approval enables clinicians to
- Admission-Day ASUC Score Validated to Predict Steroid Non-Responsehttps://reachmd.com/news/admission-day-asuc-steroid-non-response/2486351/An MDPI report describes external, single-center validation of an admission-day acute severe ulcerative colitis (ASUC) score intended to help identify pati